Supplementary Tables 1 through 13 from Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma

Supplementary Table 1: Clinicopathological Parameters of samples used Supplementary Table 2: Read Mapping Statistics of NanoChIP-seq Libraries Supplementary Table 3: Non coding RNAs associated with Somatic Promoters Supplementary Table 4: Alternative Promoters Supplementary Table 5: Spectral Counts from CRC samples of N terminal peptides predicted to be gained in GC Supplementary Table 6: HLA prediction of GC samples Supplementary Table 7: Recurrent N terminal sequences with high affinity to MHC Class I Supplementary Table 8: P values of Wilcoxon test between ACRG samples with high and low somatic promoter usage Supplementary Table 9: HLA types of healthy PBMC donors Supplementary Table 10: Peptide pools for alternative promoters Supplementary Table 11: Cytokine Responses of N terminal Peptides Supplementary Table 12: Somatic Promoters Overlapping EZH2/SUZ12 Binding Sites Supplementary Table 13: RACE Primers补充表1：所用样本的临床病理参数 补充表2：NanoChIP-seq文库的读段比对统计 补充表3：与体细胞启动子相关的非编码RNAs 补充表4：可变启动子 补充表5：胃癌（GC）中预测获得的N端肽段在结直肠癌（CRC）样本中的光谱计数 补充表6：胃癌（GC）样本的人类白细胞抗原（HLA）预测 补充表7：与主要组织相容性复合体I类（MHC Class I）具有高亲和力的重复出现N端序列 补充表8：高、低体细胞启动子使用率的ACRG样本之间的威尔科克森（Wilcoxon）检验P值 补充表9：健康外周血单个核细胞（PBMC）供体的人类白细胞抗原（HLA）分型 补充表10：可变启动子相关肽段库 补充表11：N端肽段的细胞因子应答反应 补充表12：与EZH2/SUZ12结合位点重叠的体细胞启动子 补充表13：快速扩增cDNA末端（RACE）引物